Acid secretion
aspirin enhancement 43, 44
*Helicobacter pylori* effects
  bombesin in mechanism 64
diminishment on first infection 61, 62
drug therapy considerations of altered
  pH 66
elevation with duodenal ulcer 62, 63
gastric atrophy 62
  nonulcer patients 63, 66
histamine role in gastrin-stimulated
  release 65, 66
modulation for antibiotic therapy 78
normal function 424
regulation, see Bombesin, Gastrin,
  Somatostatin
Alcohol dehydrogenase, *Helicobacter pylori* inhibitors
  bismuth 101
  proton pump inhibitors 145, 146
Amifloxacin
  bismuth effects 94
  minimum inhibitory concentration
    against *Helicobacter pylori* 74, 75
Ammonia, urease release effects
gastric pH 151
gastrin release 60
  mucosal damage 144
Amoxicillin
  meta-analysis of *Helicobacter pylori*
    therapy
  amoxicillin/nitroimidazoles 267, 268
  bismuth/nitroimidazole/amoxicillin
    272–274
  lansoprazole/clarithromycin/
    amoxicillin 298
  monotherapy 266
  omeprazole/amoxicillin 268–271
  omeprazole/amoxicillin/nitroimidazole
    277, 283
  omeprazole/clarithromycin/amoxicillin
    279, 280, 283, 284, 297, 298
  ranitidine bismuth citrate/amoxicillin
    or clarithromycin 272
  resistance 376, 380
Ampicillin, minimum inhibitory
  concentration against *Helicobacter pylori*
    74, 75
Animal models, *Helicobacter pylori*
  infection 402, 403, 405
  vaccination 405, 406, 410–413
Antimicrobial therapy, see also specific
drugs
drug interactions
  antisecretory drug interactions
    efficacy and stability effects
      153–157
    pharmacokinetics and tissue
      distribution 159–162
    pretreatment effects 162, 163
    synergistic effects 158, 159
  overview 79, 80
Antimicrobial therapy (continued)

economic analysis, see Economic analysis, Helicobacter pylori drug therapy

eradication, see Eradication, Helicobacter pylori

factors influencing effectiveness 139, 140

failure reasons 78, 79, 138, 198

ideal criteria for agents 137, 138

inoculum size 83

macrolides 77

mechanisms of action and bacterial targets 366, 367

meta-analysis, see Meta-analysis, Helicobacter pylori therapies

minimum inhibitory concentrations testing 80, 83

values 74, 75

mucosal concentration of antimicrobials 79

nitromizadoles 76

pH modulation 78

quinolones 78

regimens, overview 139, 189–199

reinfection treatment 395

resistance, see Resistance, Helicobacter pylori

susceptibility in vivo 79, 80, 138

triple therapies 76, 77, 80

uptake and barriers 135, 136

Aspirin, see Nonsteroidal anti-inflammatory drugs

ATPase, Helicobacter pylori

inhibition by bismuth 101

inhibition by proton pump inhibitors 145

pH homeostasis role 144, 145

Autoimmune response, mucosal damage in Helicobacter pylori infection 28–30

Azithromycin, minimum inhibitory concentration against Helicobacter pylori 74, 75

Aztreonam, minimum inhibitory concentration against Helicobacter pylori 74, 75

BabA, pathogenesis role 40

Bile salt, mucosal damage 30

Bismuth, see also Bismuth Subsalicylate, Colloidal bismuth subcitrate, Ranitidine bismuth citrate

absorption 420

antibacterial activity

bacteria binding 97–99, 189

time 100–102

overview 94–96

ulcer healing effects 103–106

antisecretory activity 94

comparative pharmacological activities of formulations 114

compliance in therapy 87

delivery systems for triple therapy 115

history of use 85, 419

meta-analysis of Helicobacter pylori therapy

bismuth/nitroimidazoles 268

bismuth plus therapies

bismuth/metronidazole/tetracycline with and without acid inhibitors 274–276

bismuth/nitroimidazole/amoxicillin 272–274

summary 282, 283

monotherapy 265, 266

mucosal protection 89, 91, 92

pharmacokinetics 107–112

quadruple therapies 191, 208–257

rationale for use with antibiotics 74, 78, 86, 420

retreatment following failure

bismuth triple therapy 353, 354, 360, 361

quadruple therapy 358–361

safety and tolerability 112, 113, 420

structures and solubility 88, 89

synergism with antimicrobials 96, 97

triple therapies 76, 77, 190, 191

ultrastructure effects on mucosa 93, 94

Bismuth subsalicylate

absorption 109, 111

antibacterial activity

bacteria binding 97–99

time 100–102

overview 94, 95
<table>
<thead>
<tr>
<th>Subject Index 459</th>
</tr>
</thead>
<tbody>
<tr>
<td>ulcer healing effects 103, 104</td>
</tr>
<tr>
<td>fate in gastrointestinal tract 107</td>
</tr>
<tr>
<td>mucosal concentration 109</td>
</tr>
<tr>
<td>mucosal protection 89</td>
</tr>
<tr>
<td>overview 85, 86</td>
</tr>
<tr>
<td>safety and tolerability 112</td>
</tr>
<tr>
<td>structure 87, 88</td>
</tr>
<tr>
<td>Blood group</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em> susceptibility role 5–7</td>
</tr>
<tr>
<td>mimicking by bacteria 6</td>
</tr>
<tr>
<td>Bombesin, <em>Helicobacter pylori</em> effects on release 64</td>
</tr>
<tr>
<td>CagA</td>
</tr>
<tr>
<td>conjugation role 41</td>
</tr>
<tr>
<td>pathogenesis role 10, 21, 22, 27, 28</td>
</tr>
<tr>
<td>strain classification 401</td>
</tr>
<tr>
<td>types and pathology 40, 41</td>
</tr>
<tr>
<td>vaccine targeting 408</td>
</tr>
<tr>
<td>Catalase, inhibition in bacteria by bismuth 101</td>
</tr>
<tr>
<td>Cefoxitin, minimum inhibitory concentration against <em>Helicobacter pylori</em> 74, 75</td>
</tr>
<tr>
<td>Cefuroxime, minimum inhibitory concentration against <em>Helicobacter pylori</em> 74, 75</td>
</tr>
<tr>
<td>Cephalexin, minimum inhibitory concentration against <em>Helicobacter pylori</em> 74, 75</td>
</tr>
<tr>
<td>Ciprofloxacin, minimum inhibitory concentration against <em>Helicobacter pylori</em> 74, 75</td>
</tr>
<tr>
<td>Clarithromycin, see also Macrolides meta-analysis of <em>Helicobacter pylori</em> therapy</td>
</tr>
<tr>
<td>lansoprazole/clarithromycin/amoxicillin 298</td>
</tr>
<tr>
<td>monotherapy 266</td>
</tr>
<tr>
<td>omeprazole/clarithromycin 271, 272</td>
</tr>
<tr>
<td>omeprazole/clarithromycin/amoxicillin 279, 280, 283, 284, 297, 298</td>
</tr>
<tr>
<td>omeprazole/clarithromycin/nitroimidazole 277–279, 283</td>
</tr>
<tr>
<td>ranitidine bismuth citrate/amoxicillin or clarithromycin 272</td>
</tr>
<tr>
<td>minimum inhibitory concentration against <em>Helicobacter pylori</em> 74, 75, 192</td>
</tr>
<tr>
<td>resistance 257</td>
</tr>
<tr>
<td>Clearance, <em>Helicobacter pylori</em> 179</td>
</tr>
<tr>
<td>Colloidal bismuth subcitrate</td>
</tr>
<tr>
<td>absorption 109, 111, 112</td>
</tr>
<tr>
<td>antibacterial activity</td>
</tr>
<tr>
<td>bacteria binding 97–99, 189</td>
</tr>
<tr>
<td>enzyme inhibition 100–102</td>
</tr>
<tr>
<td>overview 94–96</td>
</tr>
<tr>
<td>ulcer healing effects 103, 104</td>
</tr>
<tr>
<td>antisecretory activity 94</td>
</tr>
<tr>
<td>mucosal concentration 109</td>
</tr>
<tr>
<td>mucosal protection 91, 92</td>
</tr>
<tr>
<td>overview 85, 86</td>
</tr>
<tr>
<td>safety and tolerability 112</td>
</tr>
<tr>
<td>solubility 107, 108, 112</td>
</tr>
<tr>
<td>structure 88, 89</td>
</tr>
<tr>
<td>triple therapies 76, 77</td>
</tr>
<tr>
<td>ultrastructure effects on mucosa 93, 94</td>
</tr>
<tr>
<td>Coronary artery disease, <em>Helicobacter pylori</em> role 12, 13</td>
</tr>
<tr>
<td>Culture, <em>Helicobacter pylori</em> eradication testing 182, 183</td>
</tr>
<tr>
<td>De-Nol, see Colloidal bismuth subcitrate</td>
</tr>
<tr>
<td>Duodenal ulcer</td>
</tr>
<tr>
<td>acid load, factors affecting 8</td>
</tr>
<tr>
<td>acid secretion 62, 63</td>
</tr>
<tr>
<td>economic analysis of <em>Helicobacter pylori</em> drug therapy</td>
</tr>
<tr>
<td>proton pump inhibitor triple therapies 308</td>
</tr>
<tr>
<td>strategies for analysis 306–308</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em> eradication bleeding effects 323–325</td>
</tr>
<tr>
<td>healing effects 318–321, 340, 352</td>
</tr>
<tr>
<td>recurrence effects 321–323</td>
</tr>
<tr>
<td>testing 185</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em> infection outcome 4, 5, 8, 134, 317</td>
</tr>
<tr>
<td>relapse 317, 318</td>
</tr>
<tr>
<td>Dyspepsia</td>
</tr>
<tr>
<td>definition of nonulcer dyspepsia 329</td>
</tr>
</tbody>
</table>
Dyspepsia (continued)
- economic analysis of *Helicobacter pylori* drug therapy
  - children 310
  - guidelines 309
  - nonulcer dyspepsia 309, 310
- economic impact 330
- etiology of nonulcer dyspepsia 11
  - *Helicobacter pylori* role
    - epidemiology studies 331, 332
    - pathogenesis 335, 336
    - symptomology 332, 333
- incidence 329
- therapy of *Helicobacter pylori*-positive nonulcer dyspepsia
  - clinical trials 333–335
  - empirical treatment 330
  - endoscopy 330, 331
  - eradication therapy 336, 337, 427

Economic analysis, *Helicobacter pylori* drug therapy
- compliance problems in analysis 311
- cost-effectiveness models, assessment
  - drug costs and charge data 312, 313
  - perspective 312
  - scientific weight and variability of results 313, 314
  - decision analysis 305
- duodenal ulcer
  - proton pump inhibitor triple therapies 308
  - strategies for analysis 306–308
- dyspepsia
  - children 310
  - guidelines 309
  - nonulcer dyspepsia 309, 310
- Markov models 305
- resistance problems in analysis 311
- types of analysis 304, 305
- Elastase, immune-mediated mucosal damage 26
- Epidemiology, *Helicobacter pylori* infection 3
- Eradication, *Helicobacter pylori*, see also Antimicrobial therapy
  - clearance comparison 179
  - cost analysis of regimens 193
  - cure rates 179, 393, 396, 399
  - definition for cure 392
  - economic analysis, see Economic analysis, *Helicobacter pylori* drug therapy
  - meta-analysis, see Meta-analysis, *Helicobacter pylori* therapies
  - mucosal damage reversal 30, 31
- *Mycobacterium tuberculosis* analogy 428
- peptic ulcer effects
  - bleeding 323–325
  - healing 318–321
  - recurrence 321–323
- regimens 189–199
- relapse, see Reinfection, *Helicobacter pylori*
- retreatment following failure
  - bismuth triple therapy 353, 354, 360, 361
  - proton pump inhibitor dual therapy 354–356, 360
  - proton pump inhibitor triple therapy 356–358, 360
  - quadruple therapy 358–361
  - tests 179–187
- Erythromycin, minimum inhibitory concentration against *Helicobacter pylori* 74, 75
- Esomeprazole-based eradication regimes 231–236
- Esomeprazole, pharmacology 217–228
- Fluocloxacillin, minimum inhibitory concentration against *Helicobacter pylori* 74, 75
- Fluoroquinolone resistance
  - clinical relevance 376
  - epidemiology 375, 376
  - mechanism 376
- Furazolidone, see Metronidazole

Gastric acid, see Acid secretion

Gastric carcinoma
- *Helicobacter pylori* role
  - cytotoxins 341, 344
  - epidemiology studies 340, 341
eradication and infection prevention 344
hereditary factors 341–343
overview 8, 9, 134, 340, 424
socioeconomic factors 341
management 343, 344
Gastric lymphoma
epidemiology 345
Helicobacter pylori eradication
effects on outcome 346–348
testing 186
Helicobacter pylori role 9, 134, 345, 346
management 346–349
pathogenesis 345
staging 346
Gastric ulcer
economic impact 306
Helicobacter pylori eradication
bleeding effects 323–325
healing effects 318–321, 340, 352
recurrence effects 321–323
testing 185, 186
Helicobacter pylori infection outcome 4, 8, 134, 316–318
prevalence 316
recurrence 316, 317
Gastrin, Helicobacter pylori effects on release
eradication effects 425
histamine role in acid release 65, 66
mechanisms
ammonia release 60
cytokines 60, 61
pH alteration 60
overview 57, 58, 425
sensitivity of mucosa to gastrin 64, 65
Gastritis
associated diseases 1, 2, 7
atrophic gastritis from proton pump inhibitors 425, 426
features 423, 424
Helicobacter pylori
infection outcomes 4, 7, 8
lymphocytic gastritis 10, 11
strains and disease outcomes 9, 10, 39, 40
histologic changes 7
history of bacterial studies 2, 3
immune-mediated mucosal damage 26–30
Gastroesophageal reflux disease, Helicobacter pylori effects 11, 12
Genome, Helicobacter pylori 430
Gentamicin, minimum inhibitory concentration against Helicobacter pylori 74, 75
Guidelines for eradication 436–455
Glycocalyx, antibiotic barrier 78, 79
Histamine, role in acid release 65, 66
Histamine receptor antagonist antimicrobial drug interactions
efficacy and stability effects 153–157
pharmacokinetics and tissue distribution 159–162
pretreatment effects 162, 163
synergistic effects 158, 159
efficacy of therapy 139, 140
Helicobacter pylori modification of effects
ammonia 151
host immunity 152, 153
overview 150, 151
meta-analysis of Helicobacter pylori therapy
bismuth/metronidazole/tetracycline with and without acid inhibitors 274–276
monotherapy 266, 267
urea breath test of in vivo effects 146, 148, 149
N\(^{6}\)-Histamine methyltransferase, mucosal damage 25
Histology, Helicobacter pylori eradication testing 182
Hsp60, mucosal damage via autoimmune response 29, 30
HspA, vaccine targeting 407, 408
HspB, vaccine targeting 407, 408
Immune response
genetic variation 30
Helicobacter pylori infection 400, 401
mucosal damage 26–30
Indication for eradication 436–455
Interleukin-8, immune-mediated mucosal damage 26, 27
Invasiveness, *Helicobacter pylori* 3

Lansoprazole, see Proton pump inhibitor

Lewis antigens
Lec., expression in development 6, 7
mucosal damage via autoimmune response 29

Lipopolysaccharide, *Helicobacter pylori*

blood group antigen mimicking 6
mucosal damage 25

Lysolecithin, mucosal damage 23

Maastricht 2-2000 Consensus Report 436–455
Macrolides
resistance
clinical relevance 371, 372
epidemiology 369, 370
mechanism 370, 371, 380
therapy guidelines 77

MALT lymphoma, see Gastric lymphoma
Meta-analysis, *Helicobacter pylori*
therapies
dual therapies
amoxicillin/nitroimidazoles 266, 268
bismuth/nitroimidazoles 268
omeprazole/amoxicillin 268–271
omeprazole/clarithromycin 271, 272
ranitidine bismuth citrate/amoxicillin or clarithromycin 272
general observations 265
literature review 263, 264
monotherapies
amoxicillin 266
bismuth 265, 266
clarithromycin 266
histamine receptor antagonists 266, 267
proton pump inhibitors 267
ranitidine bismuth citrate therapies 299, 300
standardization of studies 281, 282
study inclusion criteria 264, 281
triple therapies
bismuth plus therapies
bismuth/metronidazole/tetracycline
with and without acid inhibitors 274–276
bismuth/nitroimidazole/amoxicillin
272–274
summary 282, 283
proton pump inhibitor-based triple therapies
lansoprazole/clarithromycin/
amoxicillin 298
omeprazole/amoxicillin/
nitroimidazole 277, 283
omeprazole/clarithromycin/
amoxicillin 279, 280, 283, 284,
297, 298
omeprazole/clarithromycin/
nitroimidazole 277–279, 283
pantoprazole triple therapies 298,
299
summary 283, 300, 301
Metronidazole, see also Nitroimidazoles
meta-analysis of bismuth/metronidazole/
tetracycline with and without acid inhibitors 274–276
minimum inhibitory concentration
against *Helicobacter pylori* 74, 75
quadruple therapy 249–257
resistance 76, 251, 352
triple therapy with bismuth and
tetracycline 76, 77

Minimum inhibitory concentration
antimicrobials against *Helicobacter pylori* 74, 75
definition 364
testing 80, 83

Mucus, barrier to drug uptake 135
Neutrophil, immune-mediated mucosal damage 26–28
Nitrofurantoin, minimum inhibitory concentration against *Helicobacter pylori* 74, 75
Nitroimidazoles
meta-analysis of *Helicobacter pylori*
therapy
amoxicillin/nitroimidazoles 267, 268
bismuth/nitroimidazole 268
bismuth/nitroimidazole/amoxicillin 272–274
omeprazole/amoxicillin/nitroimidazole 277, 283
omeprazole/clarithromycin/nitroimidazole 274–279, 283

resistance
clinical relevance 374, 375
epidemiology 76, 372, 373
mechanism 373, 374, 380

Nonsteroidal anti-inflammatory drugs
acid secretion enhancement by aspirin 43, 44
antibacterial effects of aspirin 47
*Helicobacter pylori* interactions in mucosal damage
dyspepsia 48
healing of lesions 50, 51
mechanisms 46, 47
overview 43
perforation and hemorrhage complications 51, 52
recommendations for treatment 52, 53
ulcer development 48–50
histological alterations in gastritis 46
mucosal damage
blood flow reduction in mechanism 45
direct damage 44
gastric adaptation effects 45, 46
indirect damage by prostaglandin synthesis 45
Nonulcer dyspepsia, see Dyspepsia

Ofloxacin, minimum inhibitory concentration against *Helicobacter pylori* 74, 75
Omeprazole, see Proton pump inhibitor
Pantoprazole, see Proton pump inhibitor
Pathogenicity island, vaccine targeting 417, 418
Penicillin
cure rate with proton pump inhibitor 76

minimum inhibitory concentration against *Helicobacter pylori* 74, 75
Peptic ulcer, see Duodenal ulcer, Gastric ulcer
Pepto-Bismol, see Bismuth Subsalicylate
Pernicious anemia, *Helicobacter pylori* role 13
Peroxy nitrite, immune-mediated mucosal damage 28
Phospholipases, *Helicobacter pylori* inhibition by bismuth 101, 102
mucosal damage 22, 23
Polymerase chain reaction, *Helicobacter pylori* eradication testing 183
Proton pump inhibitor
activation 146
antibacterial action
binding to bacteria 141–143
enzyme inhibition 143–146
overview 140, 141
profound acid inhibition effects on *Helicobacter pylori* survival 149–153
urea breath test of in vivo effects 146, 148, 149
antimicrobial drug interactions efficacy and stability effects 153–157
pharmacokinetics and tissue distribution 159–162
pretreatment effects 162, 163
synergistic effects 158, 159
atrophic gastritis association 425, 426
colonization by other bacteria in therapy 79, 151, 152
dual therapies 191–193, 421
economic analysis of triple therapies 308
efficacy of therapy 139, 140, 164, 421
*Helicobacter pylori* eradication testing 186
*Helicobacter pylori* modification of effects
ammonia 151
augmentation of activity by infection 426
host immunity 152, 153
overview 150, 151
Proton pump inhibitor (continued)
meta-analysis of *Helicobacter pylori*
therapy
bismuth/metronidazole/tetracycline
with and without acid inhibitors
274–276
esomeprazole/clarithromycin 231
monotherapy 267
omeprazole/amoxicillin 268–271
omeprazole/clarithromycin 271, 272
triple therapies
esomeprazole/clarithromycin/
amoxicillin 231–236
esomeprazole/clarithromycin/
metronidazole 231–236
lansoprazole/clarithromycin/
amoxicillin 298
omeprazole/amoxicillin/
nitroimidazole 277, 283
omeprazole/clarithromycin/
amoxicillin 279, 280, 283, 284,
297, 298
omeprazole/clarithromycin/
nitroimidazole 277–279, 283
pantoprazole triple therapies 298,
299
summary 283, 300, 301
pH measurement in stomach 150
quadruple therapies
compliance 247, 252
definition 248
delivery 254
duration and efficacy 248–251
first-line treatment 255, 256
history 247, 248
metronidazole resistance 251
overview 138, 191, 208, 247, 263
second-line treatment 252–254, 256
tolerability 252
rationale for use with antibiotics 78
retreatment following failure
dual therapy 354–356, 360
quadruple therapy 358–361
triple therapy 356–358, 360
triple therapies 164, 193–196, 199,
263, 421
types 427

Quadruple therapy, *see specific therapies*
Quinolone antibiotics, therapy guidelines
78

Ranitidine, efficacy of therapy 196, 197
Ranitidine bismuth citrate
absorption 109–111
antibacterial activity
bacteria binding 97–99
enzyme inhibition 100–102
overview 96
ulcer healing effects 104–106
antisecretory activity 94
dual therapies 87, 422, 423
efficacy of eradication therapy 197, 421
meta-analysis of *Helicobacter pylori*
therapy 272, 299, 300
mucosal concentration 108, 109
mucosal protection 89, 91, 92
overview 86, 422
safety and tolerability 113
structure 88, 89
triple therapies 77
Reactive oxygen species, immune-mediated
mucosal damage 27, 28
Reinfection, *Helicobacter pylori* incidence
179, 393, 396
sources 394, 395
treatment 395
Rescue therapies 381–391
Resistance, *Helicobacter pylori*
antibiotic spectra of resistance 75, 76,
198, 262, 368, 369, 427, 430
definitions 364, 365
fluoroquinolone resistance
clinical relevance 376
epidemiology 375, 376
mechanism 376
macrolide resistance
clinical relevance 371, 372
epidemiology 369, 370
mechanism 370, 371, 380
mechanisms 367, 368
nitroimidazole resistance
clinical relevance 374, 375
epidemiology 372, 373
mechanism 373, 374, 380
noncompliance relationship 377
problems in economic analysis 311

Rifampicin
minimum inhibitory concentration against Helicobacter pylori 74, 75
resistance 78, 377

Rosacea, Helicobacter pylori role 13

Sefsulodin, minimum inhibitory concentration against Helicobacter pylori 74, 75
Serology, Helicobacter pylori eradication testing 183, 184

Smoking, effect on eradication therapy 198

Somatostatin
effect on disease outcome 9, 10
Helicobacter pylori effects on release mechanisms
cytokines 60, 61
pH alteration 60
overview 59, 66
receptors 58
stimulation of release 59

Strain, Helicobacter pylori
effect on disease outcomes 9, 10, 39, 40
typing 22, 39, 40, 401, 402, 417

Sucralfate
efficacy in ulcer healing 125
Helicobacter pylori effects
antibiotic susceptibility 128
colonization 127
dual therapy with antibiotics 129, 130
monotherapy 128–131
mucosal injury 127, 128
triple therapy with antibiotics 129–131
mucosal protection effects 127
ulcer coating effect 126, 127

Susceptibility, Helicobacter pylori infection 4–6

Tetracycline
meta-analysis of bismuth/metronidazole/tetracycline with and without acid inhibitors 274–276

minimum inhibitory concentration against Helicobacter pylori 74, 75
quadruple therapy 249–257
resistance 377
triple therapy with bismuth and metronidazole 76, 77
Triple therapy, see specific therapies

Urea breath test
drug testing against Helicobacter pylori 146, 148, 149
Helicobacter pylori eradication testing 184–187

Urease, Helicobacter pylori
activity 3, 23
ammonia release effects
gastric pH 151
gastrin release 60
mucosal damage 144
biopsy testing 180–182, 185
inhibition
bismuth 100, 101
proton pump inhibitors 143, 144
mucosal damage 24, 25, 144
origin in stomach 2
pH optima 24
structure 23
vaccine targeting 406, 407

VacA
expression levels 40
mucosal damage 21, 22, 39
strain classification 22, 39, 40, 401, 402
structure and activity 22
vaccine targeting 408–410

Vaccination, Helicobacter pylori
adjuvants 410, 411, 430
animal models
infection 402, 403, 405
vaccination 405, 406, 410–413
antigens
CagA 408
HspA 407, 408
HspB 407, 408
multiple targeting 430
pathogenicity island targeting 417, 418
Vaccination, *Helicobacter pylori* (continued)
- antigens (continued)
  - urease 406, 407
  - VacA 407–410
- immune response 400, 401
- rationale 399, 400
- strain identification 401, 402

Virulence factors, *Helicobacter pylori*
- cytotoxins 20–22
- enzymes 22–25
- lipopolysaccharide 25

Zollinger-Ellison syndrome, effects of
- gastrin secretion 424